Generalized pustular psoriasis
MONDO:0100491A rare and extreme form of psoriasis characterized by the appearance of sterile pustules which can take many patterns. All the main pathological features of the disease are accentuated. Generalized pustular psoriasis is clinically heterogeneous in its age at onset, precipitants, severity, and natural history. Many overlapping clinical entities are recognized. There is a relationship between these entities and plaque psoriasis, as some individuals may have episodes of plaque psoriasis preceding or following the generalized pustular psoriasis, but in others generalized pustular psoriasis occurs as the sole phenotype without plaque psoriasis at any time.
17 clinical trials for this condition and its sub-types, 16 tagged with Generalized pustular psoriasis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Generalized pustular psoriasis
-
Psoriasis 14, pustular 0 trials
-
Can a single infusion stop GPP flares in their tracks?
Disease control OngoingThis study is testing whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. Adults with GPP who have had a flare will receive a single intravenous dose of spesolimab, with a possible second …
Phase 4 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug shows promise for rare skin disease over nearly 5 years
Disease control OngoingThis study looks at the long-term safety and effectiveness of spesolimab in people with generalized pustular psoriasis (GPP), a rare and severe skin condition. All 131 participants had already taken spesolimab in a previous study and will continue treatment for up to 5 years. Res…
Phase 2 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New pill shows promise for rare, severe psoriasis
Disease control OngoingThis phase 3 trial tests an oral drug called JNJ-77242113 in 19 people with two rare and severe forms of psoriasis: generalized pustular psoriasis and erythrodermic psoriasis. The study measures how many participants see improvement after 16 weeks of treatment. It is an open-labe…
Phase 3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Psoriasis flare drug study pulled before it began
Disease control CancelledThis study was designed to track the safety and effectiveness of spesolimab (Spevigo®) in Korean adults experiencing flares of generalized pustular psoriasis (GPP), a severe skin condition. The study was withdrawn before enrolling any participants, so no data were collected. It w…
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC